ATNM

Companies
Nyse American
Actinium Pharmaceuticals Inc.
Health Care
Price Chart
Overview

About ATNM

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Market Cap
$237.1M
Volume
3.6M
Avg. Volume
1.4M
P/E Ratio
-1.8405797
Dividend Yield
0.00%
Employees
52.0

Company Information

Exchange
Nyse American
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
1.33
High Correlation
Volatility
High (0.94)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
High Sensitivity
Liquidity
High Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for ATNM.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, ATNM shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$237.1M
Volume3.6M
P/E Ratio-1.84
Dividend Yield0.00%
Important Dates
Next Dividend
August 11, 2020
Next Earnings
April 1, 2025

PortfolioPilot Analysis

Get AI-powered insights on how ATNM fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025